WO2010059610A1 - Composés 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine s'utilisant comme modulateurs de la faah et utilisations desdits composés - Google Patents

Composés 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine s'utilisant comme modulateurs de la faah et utilisations desdits composés Download PDF

Info

Publication number
WO2010059610A1
WO2010059610A1 PCT/US2009/064757 US2009064757W WO2010059610A1 WO 2010059610 A1 WO2010059610 A1 WO 2010059610A1 US 2009064757 W US2009064757 W US 2009064757W WO 2010059610 A1 WO2010059610 A1 WO 2010059610A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
pyrrolo
quinolin
pyrimidin
amine
Prior art date
Application number
PCT/US2009/064757
Other languages
English (en)
Inventor
Matthew Duncton
Donogh John Roger O'mahony
Matthew Cox
Original Assignee
Renovis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovis, Inc. filed Critical Renovis, Inc.
Priority to JP2011537547A priority Critical patent/JP5539376B2/ja
Priority to CA2744343A priority patent/CA2744343A1/fr
Priority to EP09793640A priority patent/EP2364316A1/fr
Priority to US13/130,051 priority patent/US20110257208A1/en
Publication of WO2010059610A1 publication Critical patent/WO2010059610A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to novel compounds that are capable of modulating FAAH (fatty acid amide hydrolase) activity, and to pharmaceutical compositions containing such compounds.
  • the invention further relates to preparation of such compounds.
  • This invention also relates to methods for preventing and/or treating conditions that are causally related to aberrant FAAH activity or can be alleviated by modulating FAAH activity, such as pain, sleep disorders, anxiety and depression disorders, weight and eating disorders, Parkinson's disease, addiction, spasticity, inflammatory disorders, glaucoma, hypertension, or other disorders.
  • Fatty acid amide hydrolase is an integral membrane protein that degrades fatty acid primary amides and ethanolamides, a class of endogenous, lipid signaling molecules.
  • FAAH has been shown to be relevant to the in vivo degradation of anandamide (AEA), oleamide, N-palmitoyl ethanolamide (PEA), N-oleoyl ethanolamide (OEA) and N-acyl taurines.
  • AEA anandamide
  • PEA N-palmitoyl ethanolamide
  • OEA N-oleoyl ethanolamide
  • N-acyl taurines N-acyl taurines.
  • compounds, pharmaceutical compositions and methods provided are used to treat, prevent or ameliorate a range of conditions in mammals such as, but not limited to, pain of various genesis or etiology, for example acute, chronic, inflammatory and neuropathic pain, dental pain, dysmenorrhea and headache (such as migraine, cluster headache and tension headache).
  • the compounds, pharmaceutical compositions and methods provided are useful for the treatment of inflammatory pain and associated hyperalgesia and allodynia.
  • the compounds, pharmaceutical compositions and methods provided are useful for the treatment of neuropathic pain and associated hyperalgesis and allodynia (e.g.
  • the compounds, pharmaceutical compositions and methods provided are useful as anti-inflammatory agents for the treatment of arthritis, and as agents to treat Parkinson's Disease, Alzheimer's Disease, asthma, myocardial infarction, neurodegenerative disorders, spasticity, inflammatory bowel disease and autoimmune disorders, fever, atherosclerosis and cardiovascular diseases, renal disorders, bone disorders, obesity, eating disorders, nausea, emesis, cancer, memory disorders, schizophrenia, epilepsy, sleeping disorders, cognitive disorders, depression, anxiety, high blood pressure, addiction, glaucoma and lipid disorders.
  • each A and B is independently CR 2a R 2b ;
  • W and Z are independently N or CR 4 ;
  • L 1 is a single bond or substituted or unsubstituted C r C 5 alkylene, -CO-, -NHC(O)-, -OC(O)-,
  • R 1 is selected from a substituted or unsubstituted aryl or heteroaryl; each of R 2a , and R 2b is independently selected from hydrogen, and substituted or unsubstituted Ci-
  • R 3 is selected from substituted or unsubstituted Ci-C 6 alkyl, substituted or unsubstituted C 3 -
  • R 4 is independently selected from H, Ci-C 6 alkyl, substituted Ci-C 6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfo, sulfonic acid ester, azido, carboxy, substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted Cs-Cgcycloalkyl, substituted
  • each A and B is independently CR 2a R 2b ;
  • W and Z are independently N or CR 4 ;
  • L 1 is -CO-, -NHC(O)-, -OC(O)-,-SO-, or S(O) 2 -;
  • R 1 is selected from a substituted or unsubstituted aryl or heteroaryl; each of R 2a , and R 2b is independently selected from hydrogen, and substituted or unsubstituted Ci-
  • R 3 is selected from substituted or unsubstituted Ci-C 6 alkyl, substituted or unsubstituted C 3 -
  • R 4 is independently selected from H, Ci-C 6 alkyl, substituted Ci-C 6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfo, sulfonic acid ester, azido, carboxy, substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted C 3 -C 8 cycloalkyl,
  • each A and B is independently CR 2a R 2b ;
  • W and Z are independently N or CR 4 ;
  • L 1 is a single bond or substituted or unsubstituted Ci-C 5 alkylene
  • R 1 is selected from a substituted or unsubstituted aryl or heteroaryl; each of R 2a , and R 2b is independently selected from hydrogen, and substituted or unsubstituted Ci-
  • R is selected from substituted or unsubstituted Ci-C ⁇ alkyl, substituted or unsubstituted C3-
  • R 4 is independently selected from H, d-C 6 alkyl, substituted Ci-C 6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfo, sulfonic acid ester, azido, carboxy, substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted Cs-Cgcycloalkyl, substitute
  • compositions comprising a compound of the invention, and a pharmaceutical carrier, excipient or diluent.
  • the pharmaceutical composition can comprise one or more of the compounds described herein.
  • the pharmaceutical compositions of the invention can comprise a compound in combination with one or more other compounds and/or compositions having a like therapeutic effect.
  • compositions and treatment methods disclosed herein can be pharmaceutically acceptable as prepared and used.
  • methods are provided for preventing, treating or ameliorating a condition from among those listed herein, and particularly, such condition as may be associated with, e.g., arthritis, asthma, myocardial infarction, lipid disorders, cognitive disorders, anxiety, schizophrenia, depression, memory dysfunctions such as Alzheimers disease, inflammatory bowel disease and autoimmune disorders, which method comprises administering to a mammal in need thereof an amount of one or more of the compounds as provided herein, or pharmaceutical composition thereof, effective to prevent, treat or ameliorate the condition.
  • methods are provided for preventing, treating or ameliorating a variety of disease states, including the diseases associated with pain, sleep disorders, anxiety and depression disorders, weight and eating disorders, addiction, spasticity, and glaucoma, by administration of a compound such as those provided herein.
  • a neurodegenerative disease or disorder can, for example, be Parkinson's disease, Alzheimer's disease and multiple sclerosis; diseases and disorders which are mediated by or result in neuroinflammation such as, for example, encephalitis; centrally-mediated neuropsychiatric diseases and disorders such as, for example, depression mania, bipolar disease, anxiety, schizophrenia, eating disorders, sleep disorders and cognition disorders; epilepsy and seizure disorders; prostate, bladder and bowel dysfunction such as, for example urinary incontinence, urinary hesitancy, rectal hypersensitivity, fecal incontinence, benign prostatic hypertrophy and inflammatory bowel disease; respiratory and airway disease and disorders such as, for example, allergic rhinitis, asthma and reactive airway disease and chronic obstructive pulmonary disease; diseases and disorders which are mediated by or result in inflammation such as, for example rheumatoid
  • the methods comprise administering an effective condition-treating or condition-preventing amount of one or more of the compounds as provided herein, or pharmaceutical composition thereof, to the mammal in need thereof.
  • the present invention extends to the use of any of the compounds of the invention for the preparation of medicaments that may be administered for such treatments, as well as to such compounds for the treatments disclosed and specified. [0017] In additional aspects, methods are provided for synthesizing the compounds described herein, with representative synthetic protocols and pathways described below.
  • a still further object of the invention is to provide pharmaceutical compositions that are effective in the treatment or prevention of a variety of disease states, including the diseases associated with pain, sleep disorders, anxiety and depression disorders, weight and eating disorders, addiction, spasticity, intraocular pressure or other disorders.
  • a still further object of the invention is to provide a method for the treatment of the disease states recited above, by the administration of a therapeutically effective amount of the compounds of the invention, and/or the pharmaceutical compositions of the invention.
  • a yet further object of the invention is to provide formulations for the treatment of the diseases as aforesaid, by the combination of at least one of the compounds of the invention, a pharmaceutical composition of the invention, combinations thereof with other compounds and compositions having a like therapeutic effect.
  • analogue means one analogue or more than one analogue.
  • 'Acyl' or 'Alkanoyl' refers to a radical -C(O)R 20 , where R 20 is hydrogen, Ci-C 8 alkyl, C 3 -Ci 0 cycloalkyl, C 3 -C 10 cycloalkylmethyl, 4-10 membered heterocycloalkyl, aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl as defined herein.
  • Representative examples include, but are not limited to, formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl and benzylcarbonyl.
  • 'acyl' groups are -C(O)H, -C(O)-Ci-C 8 alkyl, -C(O)-(CH 2 XC 6 -Ci 0 aryl), -C(O)-(CH 2 ) t (5-10 membered heteroaryl), -C(O)-(CH 2 ) t (C 3 -Ci 0 cycloalkyl), and -C(O)-(CH 2 ) t (4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4.
  • 'Substituted Acyl' or 'Substituted Alkanoyl' refers to a radical -C(O)R 21 , wherein R 21 is independently • Ci-C 8 alkyl, substituted with halo or hydroxy; or
  • 'Acylamino' refers to a radical -NR 22 C(O)R 23 , where R 22 is hydrogen, Ci-C 8 alkyl, C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C ⁇ -Cio aryl, arylalkyl, 5-10 memberd heteroaryl or heteroarylalkyl and R is hydrogen, Ci-Cg alkyl, C3-C 1 0 cycloalkyl, 4-10 membered heterocycloalkyl, Ce- Cio aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl, as defined herein.
  • Exemplary 'acylamino' include, but are not limited to, formylamino, acetylamino, cyclohexylcarbonylamino, cyclohexylmethyl-carbonylamino, benzoylamino and benzylcarbonylamino.
  • Particular exemplary 'acylamino' groups are -NR 24 C(O)-C r C 8 alkyl, -NR 24 C(O)-(CH 2 ) t (C 6 -Ci 0 aryl), -NR 24 C(O)-(CH 2 ) t (5-10 membered heteroaryl), -NR 24 C(O)-(CH 2 ) t (C 3 -Ci 0 cycloalkyl), and -NR 24 C(O)-(CH 2 ) t (4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4, and each R 24 independently represents H or Ci-C 8 alkyl.
  • 'Substituted Acylamino' refers to a radical -NR 25 C(O)R 26 , wherein: R 25 is independently
  • R 26 is independently
  • 'Acyloxy' refers to a radical -OC(O)R 27 , where R 27 is hydrogen, C r C 8 alkyl, C 3 -Ci 0 cycloalkyl, C 3 -C 10 cycloalkylmethyl, 4-10 membered heterocycloalkyl, aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl as defined herein.
  • Representative examples include, but are not limited to, formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl and benzylcarbonyl.
  • Exemplary 'acyl' groups are -C(O)H, -C(O)-Ci-C 8 alkyl, -C(O)-(CH 2 XC 6 -Ci 0 aryl), -C(O)-(CH 2 ) t (5-10 membered heteroaryl), -C(O)-(CH 2 ) t (C 3 -Ci 0 cycloalkyl), and -C(O)-(CH 2 ) t (4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4.
  • 'Substituted Acyloxy' refers to a radical -OC(O)R 28 , wherein R 28 is independently
  • Ci-C 8 alkyl substituted with halo or hydroxy
  • alkoxy' refers to the group -OR 29 where R 29 is Ci-Cg alkyl.
  • Particular alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.
  • Particular alkoxy groups are lower alkoxy, i.e. with between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 and 4 carbon atoms.
  • Substituted alkoxy' refers to an alkoxy group substituted with one or more of those groups recited in the definition of "substituted” herein, and particularly refers to an alkoxy group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent, selected from the group consisting of amino, substituted amino, C 6 -Ci 0 aryl, aryloxy, carboxyl, cyano, C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, halogen, 5-10 membered heteroaryl, hydroxyl, nitro, thioalkoxy, thioaryloxy, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O) 2 - and aryl- S(O) 2 ".
  • Exemplary 'substituted alkoxy' groups are -O-(CH 2 ) t (C 6 -Ci 0 aryl), -O-(CH 2 ) t (5-10 membered heteroaryl), -O-(CH 2 ) t (C 3 -Ci 0 cycloalkyl), and -O-(CH 2 ) t (4- 10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, unsubstituted Ci-C 4 alkoxy, unsubstituted Ci-C 4 haloalkyl, unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • Particular exemplary 'substituted alkoxy' groups are OCF 3 , OCH 2 CF 3 , OCH 2 Ph, OCH 2 -cyclopropyl, OCH 2 CH 2 OH, and OCH 2 CH 2 NMe 2 .
  • 'Alkoxycarbonyl' refers to a radical -C(O)-OR 30 where R 30 represents an Ci-C 8 alkyl, C 3 -Ci 0 cycloalkyl, C 3 -Ci 0 cycloalkylalkyl, 4-10 membered heterocycloalkylalkyl, aralkyl, or 5-10 membered heteroarylalkyl as defined herein.
  • alkoxycarbonyl groups are C(O)O-Ci-Cg alkyl, -C(O)O- (CH 2 WC 6 -CiO aryl), -C(O)O-(CH 2 ) t (5-10 membered heteroaryl), -C(O)O-(CH 2 ) t (C 3 -Ci 0 cycloalkyl), and - C(O)O-(CH 2 ) t (4-10 membered heterocycloalkyl), wherein t is an integer from 1 to 4.
  • 'Substituted Alkoxycarbonyl' refers to a radical -C(O)-OR 31 where R 31 represents:
  • Aryloxycarbonyl' refers to a radical -C(O)-OR where R represents an C 6 -Ci 0 aryl, as defined herein.
  • exemplary "aryloxycarbonyl” groups is -C(O)O-(C 6 -Ci 0 aryl).
  • Substituted Aryloxycarbonyl' refers to a radical -C(O)-OR 33 where R 33 represents • C 6 -Ci 0 aryl, substituted with unsubstituted Ci-C 4 alkyl, halo, unsubstituted Ci-C 4 alkoxy, unsubstituted Ci-C 4 haloalkyl, unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxyl.
  • Heteroaryloxycarbonyl' refers to a radical -C(O)-OR 34 where R 34 represents a 5- 10 membered heteroaryl, as defined herein.
  • An exemplary "aryloxycarbonyl” group is -C(O)O-(5-10 membered heteroaryl).
  • 'Substituted Heteroaryloxycarbonyl' refers to a radical -C(O)-OR 35 where R 35 represents:
  • 'Alkoxycarbonylamino' refers to the group -NR 36 C(O)OR 37 , where R 36 is hydrogen, Ci -C 8 alkyl, C 3 -Ci 0 cycloalkyl, C 3 -Ci 0 cycloalkylmethyl, 4-10 membered heterocycloalkyl, aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl as defined herein, and R 37 is Ci-C 8 alkyl, C 3 -Ci 0 cycloalkyl, C 3 - Ci 0 cycloalkylmethyl, 4-10 membered heterocycloalkyl, aryl, arylalkyl, 5-10 membered heteroaryl or heteroarylalkyl as defined herein.
  • 'Alkyl' means straight or branched aliphatic hydrocarbon having 1 to 20 carbon atoms.
  • Particular alkyl has 1 to 12 carbon atoms. More particular is lower alkyl which has 1 to 6 carbon atoms. A further particular group has 1 to 4 carbon atoms.
  • Exemplary straight chained groups include methyl, ethyl n-propyl, and n-butyl. Branched means that one or more lower alkyl groups such as methyl, ethyl, propyl or butyl is attached to a linear alkyl chain, exemplary branched chain groups include isopropyl, iso- butyl, t-butyl and isoamyl.
  • Substituted alkyl' refers to an alkyl group as defined above substituted with one or more of those groups recited in the definition of "substituted” herein, and particularly refers to an alkyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent, selected from the group consisting of acyl, acylamino, acyloxy (- O-acyl or -OC(O)R 20 ), alkoxy, alkoxycarbonyl, alkoxycarbonylamino (-NR -alkoxycarbonyl or -NH- C(O)-OR 27 ), amino, substituted amino, aminocarbonyl (carbamoyl or amido or -C(O)-NR 2 ), aminocarbonylamino (-NR -C(O)-NR 2 ), aminocarbonyloxy (-O-C(O)-NR 2) , aminosulfonyl
  • 'substituted alkyl' refers to a Ci-C 8 alkyl group substituted with halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -NR " SO 2 R “ , -SO 2 NR R “ , -C(O)R “ , -C(O)OR “ , -OC(O)R “ , -NR '” C(O)R “ , - C(O)NR R “ , -NR “ R “ , or -(CR '” R “” ) m OR " ; wherein each R " is independently selected from H, Q-C 8 alkyl, -(CH 2 WC 6 -Ci 0 aryl), -(CH 2 ) t (5-10 membered heteroaryl), -(CH 2 XC 3 -Ci 0 cycloalkyl), and -(CH 2 ) t (4-10 membered hetero
  • alkylene' refers to divalent saturated alkene radical groups having 1 to 11 carbon atoms and more particularly 1 to 6 carbon atoms which can be straight-chained or branched. This term is exemplified by groups such as methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), the propylene isomers (e.g., - CH 2 CH 2 CH 2 - and -CH(CH 3 )CH 2 -) and the like.
  • Substituted alkylene' refers to those groups recited in the definition of "substituted” herein, and particularly refers to an alkylene group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, amino-carbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O) 2 - and aryl-S(O)
  • alkenyl' refers to monovalent olefinically unsaturated hydrocarbyl groups preferably having
  • 'Substituted alkenyl' refers to those groups recited in the definition of 'substituted' herein, and particularly refers to an alkenyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-, alkyl-
  • alkenylene' refers to divalent olefinically unsaturated hydrocarbyl groups particularly having up to about 11 carbon atoms and more particularly 2 to 6 carbon atoms which can be straight- chained or branched and having at least 1 and particularly from 1 to 2 sites of olefinic unsaturation.
  • Alkynyl' refers to acetylenically or alkynically unsaturated hydrocarbyl groups particularly having 2 to 11 carbon atoms, and more particularly 2 to 6 carbon atoms which can be straight-chained or branched and having at least 1 and particularly from 1 to 2 sites of alkynyl unsaturation.
  • alkynyl groups include acetylenic, ethynyl (-C ⁇ CH), propargyl (-CH 2 C ⁇ CH), and the like.
  • Substituted alkynyl' refers to those groups recited in the definition of "substituted” herein, and particularly refers to an alkynyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S(O)-,
  • 'Amino' refers to the radical -NH 2 .
  • 'Substituted amino' refers to an amino group substituted with one or more of those groups recited in the definition of 'substituted' herein, and particularly refers to the group -N(R 38 ) 2 where each
  • R 38 is independently selected from:
  • Ci-Cg alkyl substituted with halo or hydroxy
  • R 38 groups When both R 38 groups are hydrogen, -N(R 38 ) 2 is an amino group.
  • Exemplary ' substituted amino' groups are -NR 39 -C r C 8 alkyl, -NR 39 -(CH 2 ) t (C 6 -Ci 0 aryl), -NR 39 -(CH 2 ) t (5- 10 membered heteroaryl), -NR 39 - (CH 2 ) t (C 3 -Cio cycloalkyl), and -NR 39 -(CH 2 ) t (4- 10 membered heterocycloalkyl), wherein t is an integer from 0 to 4, each R 39 independently represents H or Ci-C 8 alkyl; and any alkyl groups present, may themselves be substituted by halo, substituted or unsubstituted amino, or hydroxy; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted
  • substituted amino includes the groups alkylamino, substituted alkylamino, alkylarylamino, substituted alkylarylamino, arylamino, substituted arylamino, dialkylamino and substituted dialkylamino as defined below.
  • 'Alkylamino' refers to the group -NHR 40 , wherein R 40 is Ci-C 8 alkyl;
  • Substituted Alkylamino' refers to the group -NHR 41 , wherein R 41 is Ci-C 8 alkyl; and the alkyl group is substituted with halo, substituted or unsubstituted amino, hydroxy, C3-C 1 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci O aryl, 5-10 membered heteroaryl, aralkyl or heteroaralkyl; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, unsubstituted Ci-C 4 alkoxy, unsubstituted Ci-C 4 haloalkyl, unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • Alkylarylamino' refers to the group -NR 42 R 43 , wherein R 42 is aryl and R 43 is Ci-C 8 alkyl.
  • Substituted Alkylarylamino' refers to the group -NR 44 R 45 , wherein R 44 is aryl and R 45 is C r
  • 'Arylamino' means a radical -NHR 46 where R 46 is selected from C 6 -Ci 0 aryl and 5-10 membered heteroaryl as defined herein.
  • Substituted Arylamino' refers to the group -NHR 47 , wherein R 47 is independently selected from C 6 -Ci 0 aryl and 5-10 membered heteroaryl; and any aryl or heteroaryl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, cyano, unsubstituted Ci-C 4 alkoxy, unsubstituted Ci-C 4 haloalkyl, unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • 'Dialkylamino' refers to the group -NR 48 R 49 , wherein each of R 48 and R 49 are independently selected from Ci-Cg alkyl.
  • 'Substituted Dialkylamino' refers to the group -NR 50 R 51 , wherein each of R 59 and R 51 are independently selected from Ci-Cg alkyl; and at least one of the alkyl groups is independently substituted with halo, hydroxy, C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, 5-10 membered heteroaryl, aralkyl or heteroaralkyl; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, unsubstituted Ci-C 4 alkoxy, unsubstituted Cr 4 haloalkyl, unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • 'Diarylamino' refers to the group -NR 52 R 53 , wherein each of R 52 and R 53 are independently selected from C 6 -Ci 0 aryl.
  • 'Aminosulfonyl' or 'Sulfonamide' refers to the radical -S(O 2 )NH 2 .
  • 'Substituted aminosulfonyl' or 'substituted sulfonamide' refers to a radical such as -
  • each R 548 is independently selected from:
  • Ci-Cg alkyl C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
  • Exemplary 'substituted aminosulfonyl' or 'substituted sulfonamide' groups are -S(O 2 )N(R 55 )- Ci-C 8 alkyl, -S(O 2 )N(R 55 )-(CH 2 ) t (C 6 -Ci 0 aryl), -S(O 2 )N(R 55 )-(CH 2 ) t (5-10 membered heteroaryl), - S(0 2 )N(R 55 )-(CH 2 ) t (C 3 -Cio cycloalkyl), and -S(O 2 )N(R 55 )-(CH 2 ) t (4- 10 membered heterocycloalkyl), wherein t is an integer from 0 to 4; each R 55 independently represents H or Ci-Cg alkyl; and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may
  • 'Aralkyl' or 'arylalkyl' refers to an alkyl group, as defined above, substituted with one or more aryl groups, as defined above. Particular aralkyl or arylalkyl groups are alkyl groups substituted with one aryl group.
  • 'Substituted Aralkyl' or 'substituted arylalkyl' refers to an alkyl group, as defined above, substituted with one or more aryl groups; and at least one of the aryl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, cyano, unsubstituted Ci-C 4 alkoxy, unsubstituted Ci-C 4 haloalkyl, unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • 'Aryl' refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • aryl refers to an aromatic ring structure, mono-cyclic or poly-cyclic that includes from 5 to 12 ring members, more usually
  • aryl group is a monocyclic ring system it preferentially contains 6 carbon atoms.
  • Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene and trinaphthalene.
  • Particularly aryl groups include phenyl
  • 'Substituted Aryl' refers to an aryl group substituted with one or more of those groups recited in the definition of 'substituted' herein, and particularly refers to an aryl group that may optionally be substituted with 1 or more substituents, for instance from 1 to 5 substituents, particularly 1 to 3 substituents, in particular 1 substituent.
  • 'Substituted Aryl' refers to an aryl group substituted with one or more of groups selected from halo, Ci-C 8 alkyl, Ci-C 8 haloalkyl, cyano, hydroxy, Ci-C 8 alkoxy, and amino.
  • R 56 and R 57 may be hydrogen and at least one of R 56 and R 57 is each independently selected from Ci-C 8 alkyl, Ci-C 8 haloalkyl, 4-10 membered heterocycloalkyl, alkanoyl, Q- C 8 alkoxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR 58 COR 59 , NR 58 SOR 59 ⁇ NR 58 SO 2 R 59 , COOalkyl, COOaryl, CONR 58 R 59 , CONR 58 OR 59 , NR 58 R 59 , SO 2 NR 58 R 59 , S-alkyl, SOalkyl, SO 2 alkyl, Saryl, SOaryl, SO 2 aryl; or R 56 and R 57 may be joined to form a cyclic ring (saturated or unsaturated) from 5 to 8 atoms, optionally containing one or
  • R 60 , and R 61 are independently hydrogen, Ci-C 8 alkyl, Ci -C 4 haloalkyl, C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, substituted aryl, 5-10 membered heteroaryl.
  • 'Fused Aryl' refers to an aryl having two of its ring carbon in common with a second aryl ring or with an aliphatic ring.
  • Arylalkyloxy' refers to an -O-alkylaryl radical where alkylaryl is as defined herein.
  • Substituted Arylalkyloxy' refers to an -O-alkylaryl radical where alkylaryl is as defined herein; and any aryl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, cyano, unsubstituted Ci-C 4 alkoxy, unsubstituted C r4 haloalkyl, unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • 'Azido' refers to the radical -N 3 .
  • Carbamoyl or amido' refers to the radical -C(O)NH 2 .
  • R 62 is independently
  • Ci-C 8 alkyl C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
  • Exemplary 'Substituted Carbamoyl' groups are -C(O) alkyl, -C(O)NR 64 -(CH 2 ) t (C 6 -Ci 0 aryl),
  • each R 64 independently represents H or Ci-C 8 alkyl and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, unsubstituted Ci-C 4 alkoxy, unsubstituted
  • Ci-C 4 haloalkyl unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • Carboxy' refers to the radical -C(O)OH.
  • 'Cycloalkyl' refers to cyclic non-aromatic hydrocarbyl groups having from 3 to 10 carbon atoms.
  • Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl.
  • 'Substituted cycloalkyl' refers to a cycloalkyl group as defined above substituted with one or more of those groups recited in the definition of 'substituted' herein, and particularly refers to a cycloalkyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, in particular 1 substituent
  • 'Halo' or 'halogen' refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I). Particular halo groups are either fluoro or chloro.
  • Hetero when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g. heteroalkyl, cycloalkyl, e.g. heterocycloalkyl, aryl, e.g. heteroaryl, cycloalkenyl, e.g. cycloheteroalkenyl, and the like having from 1 to 5, and particularly from 1 to 3 heteroatoms.
  • Heteroaryl' means an aromatic ring structure, mono-cyclic or polycyclic, that includes one or more heteroatoms and 5 to 12 ring members, more usually 5 to 10 ring members.
  • the heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a bicyclic structure formed from fused five and six membered rings or two fused six membered rings or, by way of a further example, two fused five membered rings.
  • Each ring may contain up to four heteroatoms typically selected from nitrogen, sulphur and oxygen.
  • the heteroaryl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom.
  • the heteroaryl ring contains at least one ring nitrogen atom.
  • the nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.
  • Examples of five membered monocyclic heteroaryl groups include but are not limited to pyrrole, furan, thiophene, imidazole, furazan, oxazole, oxadiazole, oxatriazole, isoxazole, thiazole, isothiazole, pyrazole, triazole and tetrazole groups.
  • Examples of six membered monocyclic heteroaryl groups include but are not limited to pyridine, pyrazine, pyridazine, pyrimidine and triazine.
  • bicyclic heteroaryl groups containing a five membered ring fused to another five membered ring include but are not limited to imidazothiazole and imidazoimidazole.
  • bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzfuran, benzthiophene, benzimidazole, benzoxazole, isobenzoxazole, benzisoxazole, benzthiazole, benzisothiazole, isobenzofuran, indole, isoindole, isoindolone, indolizine, indoline, isoindoline, purine (e.g., adenine, guanine), indazole, pyrazolopyrimidine, triazolopyrimidine, benzodioxole and pyrazolopyridine groups.
  • bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinoline, isoquinoline, chroman, thiochroman, chromene, isochromene, chroman, isochroman, benzodioxan, quinolizine, benzoxazine, benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and pteridine groups.
  • heteroaryl groups are those derived from thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.
  • Examples of representative heteroaryls include the following: wherein each Y is selected from carbonyl, N, NR , O and S; and R is independently hydrogen, Ci-Cg alkyl, C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, and 5-10 membered heteroaryl.
  • Examples of representative aryl having hetero atoms containing substitution include the following:
  • each W is selected from C(R 66 ) 2 , NR 66 , O and S; and each Y is selected from carbonyl, NR 66 , O and S; and R 66 is independently hydrogen, Ci-C 8 alkyl, C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, and 5-10 membered heteroaryl.
  • heterocycloalkyl refers to a 4-10 membered, stable heterocyclic non-aromatic ring and/or including rings containing one or more heteroatoms independently selected from N, O and S, fused thereto.
  • a fused heterocyclic ring system may include carbocyclic rings and need only include one heterocyclic ring.
  • heterocyclic rings include, but are not limited to, morpholine, piperidine (e.g. 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (e.g.
  • thiomorpholine and its S-oxide and S,S-dioxide particularly thiomorpholine
  • Still further examples include azetidine, piperidone, piperazone, and N-alkyl piperidines such as N-methyl piperidine.
  • heterocycloalkyl groups are shown in the following illustrative examples: wherein each W is selected from CR 67 , C(R 67 ) 2 , NR 67 , O and S; and each Y is selected from NR 67 , O and S; and R 67 is independently hydrogen, Ci-C 8 alkyl, C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, 5-10 membered heteroaryl,
  • These heterocycloalkyl rings may be optionally substituted with one or more groups selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl (carbamoyl or amido), aminocarbonylamino, aminosulfonyl, sulfonylamino, aryl, aryloxy, azido
  • 'Hydroxy' refers to the radical -OH.
  • 'Nitro' refers to the radical -NO 2 .
  • 'Substituted' refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s).
  • substituted groups are substituted with one or more substituents, particularly with 1 to 3 substituents, in particular with one substituent group.
  • the substituent group or groups are selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -NR 72 SO 2 R 73 , -SO 2 NR 73 R 72 , -C(O)R 73 , -C(O)OR 73 , -OC(O)R 73 , -NR 72 C(O)R 73 , -C(O)NR 73 R 72 , -NR 73 R 72 , -(CR 72 R 72 ) m OR 72 , wherein, each R 73 is independently selected from H, Ci-C 8 alkyl, -(CH 2 XC 6 -Ci 0 aiyl), -(CH 2 ) t (5-10 membered heteroaryl), -(CH 2 XC 3 -Ci 0 cycloalkyl), and -(CH 2 ) t (4-10 membered heterocycloalky
  • any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, unsubstituted Ci-C 4 alkoxy, unsubstituted Q- C 4 haloalkyl, unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • Each R independently represents H or Ci-C 6 alkyl.
  • Substituted sulfanyl refers to the group -SR 74 , wherein R 74 is selected from:
  • Ci-C 8 alkyl C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
  • Exemplary 'substituted sulfanyl' groups are -S-(Ci-C 8 alkyl) and -S-(C 3 -Ci 0 cycloalkyl), -S-
  • (CH 2 ) t (4- 10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, unsubstituted Ci-C 4 alkoxy, unsubstituted Ci-C 4 haloalkyl, unsubstituted Ci-C 4 hydroxyalkyl, or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • the term 'substituted sulfanyl' includes the groups
  • 'Alkylthio' or 'Alkylsulfanyl' refers to a radical -SR 75 where R 75 is a Ci-C 8 alkyl or group as defined herein. Representative examples include, but are not limited to, methylthio, ethylthio, propylthio and butylthio.
  • 'Substituted Alkylthio 'or 'substituted alkylsulfanyl refers to the group -SR 76 where R 76 is a
  • Ci-Cg alkyl substituted with halo, substituted or unsubstituted amino, or hydroxy.
  • 'Cycloalkylthio' or 'Cycloalkylsulfanyl' refers to a radical -SR 77 where R 77 is a C 3 -Ci 0 cycloalkyl or group as defined herein.
  • Representative examples include, but are not limited to, cyclopropylthio, cyclohexylthio, and cyclopentylthio.
  • 'Substituted cycloalkylthio' or 'substituted cycloalkylsulfanyl' refers to the group -SR 78 where R 78 is a C 3 -Ci 0 cycloalkyl, substituted with halo, substituted or unsubstituted amino, or hydroxy.
  • 'Arylthio' or 'Arylsulfanyl' refers to a radical -SR 79 where R 79 is a C 6 -Ci 0 aryl group as defined herein.
  • 'Heteroarylthio' or 'Heteroarylsulfanyl' refers to a radical -SR 80 where R 80 is a 5- 10 membered heteroaryl group as defined herein.
  • 'Substituted sulfmyl' refers to the group -S(O)R 81 , wherein R 81 is selected from:
  • Ci-C 8 alkyl C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
  • Exemplary 'substituted sulfmyl' groups are -S(O)-(C r C 8 alkyl) and -S(O)-(C 3 -Ci 0 cycloalkyl), -S(O)-(CH 2 ) t (C 6 -Ci 0 aryl), -S(O)-(CH 2 ) t (5-10 membered heteroaryl), -S(O)-(CH 2 ) t (C 3 -Ci 0 cycloalkyl), and -S(O)-(CH 2 ) t (4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, unsubstituted Ci-C 4 alkoxy, unsubstituted Ci-C
  • Ci-C 4 hydroxyalkyl or unsubstituted Ci-C 4 haloalkoxy or hydroxy.
  • substituted sulfmyl includes the groups 'alkylsulfinyl', 'substituted alkylsulfinyl', 'cycloalkylsulfinyl', 'substituted cycloalkylsulfinyl',
  • Alkylsulfinyl' refers to a radical -S(O)R 82 where R 82 is a Ci-C 8 alkyl group as defined herein.
  • Representative examples include, but are not limited to, methylsulfinyl, ethylsulfinyl, propylsulfinyl and butylsulfinyl.
  • Substituted Alkylsulfinyl refers to a radical -S(O)R 83 where R 83 is a C r C 8 alkyl group as defined herein, substituted with halo, substituted or unsubstituted amino, or hydroxy.
  • 'Cycloalkylsulfinyl' refers to a radical -S(O)R 84 where R 84 is a C 3 -Ci 0 cycloalkyl or group as defined herein. Representative examples include, but are not limited to, cyclopropylsulfinyl, cyclohexylsulfinyl, and cyclopentylsulfinyl. Exemplary 'cycloalkylsulfinyl' groups are S(O)-C 3 -Ci 0 cycloalkyl.
  • cycloalkylsulfinyl refers to the group -S(O)R 85 where R 85 is a C 3 -Ci 0 cycloalkyl, substituted with halo, substituted or unsubstituted amino, or hydroxy.
  • 'Arylsulfinyl' refers to a radical -S(O)R 86 where R 86 is a C 6 -Ci 0 aryl group as defined herein.
  • Heteroarylsulfinyl' refers to a radical -S(O)R 87 where R 87 is a 5-10 membered heteroaryl group as defined herein.
  • Substituted sulfonyl' refers to the group -S(O) 2 R 88 , wherein R 88 is selected from:
  • Ci-Cg alkyl C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
  • Exemplary 'substituted sulfonyl' groups are -S(O) 2 -(Ci-C 8 alkyl) and -S(O) 2 -(C 3 -Ci 0 cycloalkyl), -S(O) 2 -(CH 2 WC 6 -Ci 0 atyl), -S(O) 2 -(CH 2 ) t (5-10 membered heteroaryl), -S(O) 2 -(CH 2 WC 3 -Ci 0 cycloalkyl), and -S(O) 2 -(CH 2 ) t (4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted Ci-C 4 alkyl, halo, unsubstituted Ci-C 4 alkoxy, unsubstit
  • substituted sulfonyl includes the groups alkylsulfonyl, substituted alkylsulfonyl, cycloalkylsulfonyl, substituted cycloalkylsulfonyl, arylsulfonyl and heteroarylsulfonyl.
  • Alkylsulfonyl refers to a radical -S(O) 2 R 89 where R 89 is an Ci-C 8 alkyl group as defined herein.
  • Representative examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, propylsulfonyl and butylsulfonyl.
  • Substituted Alkylsulfonyl refers to a radical -S(O) 2 R 90 where R 90 is an C r C 8 alkyl group as defined herein, substituted with halo, substituted or unsubstituted amino, or hydroxy.
  • 'Cycloalkylsulfonyl' refers to a radical -S(O) 2 R 91 where R 91 is a C3-C 1 0 cycloalkyl or group as defined herein.
  • Representative examples include, but are not limited to, cyclopropylsulfonyl, cyclohexylsulfonyl, and cyclopentylsulfonyl.
  • Substituted cycloalkylsulfonyl' refers to the group -S(O) 2 R 92 where R 92 is a C 3 -Ci 0 cycloalkyl, substituted with halo, substituted or unsubstituted amino, or hydroxy.
  • Arylsulfonyl' refers to a radical -S(O) 2 R 93 where R 93 is an C 6 -Ci 0 aryl group as defined herein.
  • Heteroarylsulfonyl refers to a radical -S(O) 2 R 94 where R 94 is an 5-10 membered heteroaryl group as defined herein.
  • 'Sulfo' or 'sulfonic acid' refers to a radical such as -SO 3 H.
  • 'Substituted sulfo' or 'sulfonic acid ester' refers to the group -S(O) 2 OR 95 , wherein R 95 is selected from:
  • Ci-Cg alkyl C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl; or
  • Exemplary 'Substituted sulfo' or 'sulfonic acid ester' groups are -S(O) 2 -O-(Ci-Cg alkyl) and -S(O) 2 -O-(C 3 -Ci 0 cycloalkyl), -S(O) 2 -O-(CH 2 ) t (C 6 -Ci 0 aryl), -S(O) 2 -O-(CH 2 ) t (5-10 membered heteroaryl), -S(O) 2 -O-(CH 2 WC 3 -Ci 0 cycloalkyl), and -S(O) 2 -O-(CH 2 ) t (4-10 membered heterocycloalkyl), wherein t is an integer from 0 to 4 and any aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups present, may themselves be substituted by unsubstituted Ci-C 4 al
  • 'Thiol' refers to the group -SH.
  • 'Aminocarbonylamino' refers to the group -NR 96 C(O)NR 96 R 96 where each R 96 is independently hydrogen Ci-C 8 alkyl, C 3 -Ci 0 cycloalkyl, 4-10 membered heterocycloalkyl, C 6 -Ci 0 aryl, aralkyl, 5-10 membered heteroaryl, and heteroaralkyl, as defined herein; or where two R 96 groups, when attached to the same N, are joined to form an alkylene group.
  • 'Bicycloaryl' refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent bicycloaromatic ring system.
  • Typical bicycloaryl groups include, but are not limited to, groups derived from indane, indene, naphthalene, tetrahydronaphthalene, and the like.
  • an aryl group comprises from 8 to 11 carbon atoms.
  • 'Bicycloheteroaryl' refers to a monovalent bicycloheteroaromatic group derived by the removal of one hydrogen atom from a single atom of a parent bicycloheteroaromatic ring system.
  • Typical bicycloheteroaryl groups include, but are not limited to, groups derived from benzofuran, benzimidazole, benzindazole, benzdioxane, chromene, chromane, cinnoline, phthalazine, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, benzothiazole, benzoxazole, naphthyridine, benzoxadiazole, pteridine, purine, benzopyran, benzpyrazine, pyridopyrimidine, quinazoline, quinoline, quinolizine, quinoxaline, benzomorphan, tetrahydroisoquinoline, tetrahydroquinoline, and the like.
  • the bicycloheteroaryl group is between 9-11 membered bicycloheteroaryl, with 5-10 membered heteroaryl being particularly preferred.
  • Particular bicycloheteroaryl groups are those derived from benzothiophene, benzofuran, benzothiazole, indole, quinoline, isoquinoline, benzimidazole, benzoxazole and benzdioxane.
  • 'Cycloalkylalkyl refers to a radical in which a cycloalkyl group is substituted for a hydrogen atom of an alkyl group.
  • Typical cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, and cyclooctylethyl, and the like.
  • Heterocycloalkylalkyl refers to a radical in which a heterocycloalkyl group is substituted for a hydrogen atom of an alkyl group.
  • Typical heterocycloalkylalkyl groups include, but are not limited to, pyrrolidinylmethyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyrrolidinylethyl, piperidinylethyl, piperazinylethyl, morpholinylethyl, and the like.
  • 'Cycloalkenyl' refers to cyclic hydrocarbyl groups having from 3 to 10 carbon atoms and having a single cyclic ring or multiple condensed rings, including fused and bridged ring systems and having at least one and particularly from 1 to 2 sites of olefmic unsaturation.
  • Such cycloalkenyl groups include, by way of example, single ring structures such as cyclohexenyl, cyclopentenyl, cyclopropenyl, and the like.
  • cycloalkenyl refers to those groups recited in the definition of "substituted” herein, and particularly refers to a cycloalkenyl group having 1 or more substituents, for instance from 1 to 5 substituents, and particularly from 1 to 3 substituents, selected from the group consisting of acyl, acylamino, acyloxy, alkoxy, substituted alkoxy, alkoxycarbonyl, alkoxycarbonylamino, amino, substituted amino, aminocarbonyl, aminocarbonylamino, aminocarbonyloxy, aryl, aryloxy, azido, carboxyl, cyano, cycloalkyl, substituted cycloalkyl, halogen, hydroxyl, keto, nitro, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioketo, thiol, alkyl-S(O)-, aryl-S
  • Cycloalkenyl refers to a cycloalkenyl having two of its ring carbon atoms in common with a second aliphatic or aromatic ring and having its olefmic unsaturation located to impart aromaticity to the cycloalkenyl ring.
  • 'Ethylene' refers to substituted or unsubstituted -(C-C)-.
  • 'Hydrogen bond donor' group refers to a group containg O-H, or N-H functionality.
  • Examples of 'hydrogen bond donor' groups include -OH, -NH 2 , and -NH-R 97 and wherein R 97 is alkyl, acyl, cycloalkyl, aryl, or heteroaryl.
  • 'Dihydroxyphosphoryl' refers to the radical -PO(OH) 2 .
  • substituted herein, and particularly refers to a dihydroxyphosphoryl radical wherein one or both of the hydroxyl groups are substituted. Suitable substituents are described in detail below.
  • 'Aminohydroxyphosphoryl' refers to the radical -PO(OH)NH 2 .
  • substituted herein, and particularly refers to an aminohydroxyphosphoryl wherein the amino group is substituted with one or two substituents. Suitable substituents are described in detail below. In certain embodiments, the hydroxyl group can also be substituted.
  • 'Nitrogen-Containing Heterocycloalkyl' group means a 4 to 7 membered non-aromatic cyclic group containing at least one nitrogen atom, for example, but without limitation, morpholine, piperidine
  • pyrrolidine e.g. 2-pyrrolidinyl and 3-pyrrolidinyl
  • azetidine e.g. 2-pyrrolidone, imidazoline, imidazolidinone, 2-pyrazoline, pyrazolidine, piperazine, and N-alkyl piperazines such as N-methyl piperazine.
  • Particular examples include azetidine, piperidone and piperazone.
  • heterocyclic ring may have one to four heteroatoms so long as the heteroaromatic ring is chemically feasible and stable.
  • 'Pharmaceutically acceptable means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
  • 'Pharmaceutically acceptable salt' refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts.
  • such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid
  • Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • pharmaceutically acceptable cation refers to an acceptable cationic counter- ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like.
  • 'Pharmaceutically acceptable vehicle' refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.
  • 'Prodrugs' refers to compounds, including derivatives of the compounds of the invention, which have cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.
  • 'Solvate' refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association includes hydrogen bonding. Conventional solvents include water, ethanol, acetic acid and the like.
  • the compounds of the invention may be prepared e.g. in crystalline form and may be solvated or hydrated.
  • Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. 'Solvate' encompasses both solution-phase and isolable solvates. Representative solvates include hydrates, ethanolates and methanolates.
  • 'Subject' includes humans.
  • the terms 'human', 'patient' and 'subject' are used interchangeably herein.
  • 'Therapeutically effective amount means the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease.
  • the "therapeutically effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.
  • 'Preventing' or 'prevention' refers to a reduction in risk of acquiring or developing a disease or disorder (i.e., causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to a disease-causing agent, or predisposed to the disease in advance of disease onset.
  • the term 'prophylaxis' is related to 'prevention', and refers to a measure or procedure the purpose of which is to prevent, rather than to treat or cure a disease.
  • Non- limiting examples of prophylactic measures may include the administration of vaccines; the administration of low molecular weight heparin to hospital patients at risk for thrombosis due, for example, to immobilization; and the administration of an anti-malarial agent such as chloroquine, in advance of a visit to a geographical region where malaria is endemic or the risk of contracting malaria is high.
  • an anti-malarial agent such as chloroquine
  • 'Treating' or 'treatment' of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof).
  • 'treating' or 'treatment' refers to ameliorating at least one physical parameter, which may not be discernible by the subject.
  • 'treating' or 'treatment' refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • "treating" or "treatment” relates to slowing the progression of the disease.
  • ranges are referred to herein, for example but without limitation, Ci-Cg alkyl
  • the citation of a range should be considered a representation of each member of said range.
  • Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but in the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
  • Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides.
  • Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are particular prodrugs.
  • double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
  • the term 'isotopic variant' refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such compound.
  • an 'isotopic variant' of a compound can contain one or more non-radioactive isotopes, such as for example, deuterium ( 2 H or D), carbon- 13 ( 13 C), nitrogen- 15 ( 15 N), or the like.
  • the following atoms, where present, may vary, so that for example, any hydrogen may be 2 HZO, any carbon may be 13 C, or any nitrogen may be 15 N, and that the presence and placement of such atoms may be determined within the skill of the art.
  • the invention may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • compounds may be prepared that are substituted with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N, and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • PET Positron Emission Topography
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)- isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof.
  • a mixture containing equal proportions of the enantiomers is called a 'racemic mixture'.
  • 'Tautomers' refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons.
  • two structures may be in equilibrium through the movement of ⁇ electrons and an atom (usually H).
  • enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base.
  • Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base.
  • Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
  • a pure enantiomeric compound is substantially free from other enantiomers or stereoisomers of the compound (i.e., in enantiomeric excess).
  • an "S" form of the compound is substantially free from the "R” form of the compound and is, thus, in enantiomeric excess of the "R” form.
  • enantiomerically pure or “pure enantiomer” denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the enantiomer.
  • the weights are based upon total weight of all enantiomers or stereoisomers of the compound.
  • the term “enantiomerically pure R-compound” refers to at least about 80% by weight R-compound and at most about 20% by weight S-compound, at least about 90% by weight R-compound and at most about 10% by weight S-compound, at least about 95% by weight R-compound and at most about 5% by weight S-compound, at least about 99% by weight R-compound and at most about 1% by weight S-compound, at least about 99.9% by weight R-compound or at most about 0.1% by weight S-compound.
  • the weights are based upon total weight of compound.
  • the term “enantiomerically pure S-compound” or “S-compound” refers to at least about 80% by weight S-compound and at most about 20% by weight R-compound, at least about 90% by weight S-compound and at most about 10% by weight R-compound, at least about 95% by weight S-compound and at most about 5% by weight R-compound, at least about 99% by weight S-compound and at most about 1% by weight R-compound or at least about 99.9% by weight S-compound and at most about 0.1% by weight R-compound.
  • the weights are based upon total weight of compound.
  • an enantiomerically pure compound or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof can be present with other active or inactive ingredients.
  • a pharmaceutical composition comprising enantiomerically pure R- compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure R- compound.
  • the enantiomerically pure R-compound in such compositions can, for example, comprise, at least about 95% by weight R-compound and at most about 5% by weight S- compound, by total weight of the compound.
  • a pharmaceutical composition comprising enantiomerically pure S-compound can comprise, for example, about 90% excipient and about 10% enantiomerically pure S-compound.
  • the enantiomerically pure S-compound in such compositions can, for example, comprise, at least about 95% by weight S-compound and at most about 5% by weight R-compound, by total weight of the compound.
  • the active ingredient can be formulated with little or no excipient or carrier.
  • the compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof.
  • the present invention provides compounds useful for preventing and/or treating a broad range of conditions, among them, pain, sleep disorders, anxiety and depression disorders, weight and eating disorders, Parkinson's disease, addiction, spasticity, inflammatory disorders, glaucoma or other disorders.
  • compounds are provided that have formula I:
  • each A and B is independently CR 2a R 2b ;
  • W and Z are independently N or CR 4 ;
  • L 1 is a single bond or substituted or unsubstituted C 1 -C 5 alkylene, -CO-, -NHC(O)-, -OC(O)-,
  • R 1 is selected from a substituted or unsubstituted aryl or heteroaryl; each of R 2a , and R 2b is independently selected from hydrogen, and substituted or unsubstituted Ci-
  • R 3 is selected from substituted or unsubstituted Ci-C 6 alkyl, substituted or unsubstituted C 3 -
  • R 4 is independently selected from H, Ci-C ⁇ alkyl, substituted Ci-C ⁇ alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfo, sulfonic acid ester, azido, carboxy, substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted Cs-Cgcycloalkyl, substituted
  • each A and B is independently CR 2a R 2b ;
  • W and Z are independently N or CR 4 ;
  • L 1 is -CO-, -NHC(O)-, -OC(O)-,-SO-, or S(O) 2 -;
  • R 1 is selected from a substituted or unsubstituted aryl or heteroaryl; each of R 2a , and R 2b is independently selected from hydrogen, and substituted or unsubstituted Q-
  • R is selected from substituted or unsubstituted Ci-C ⁇ alkyl, substituted or unsubstituted C3-
  • R 4 is independently selected from H, Ci-C 6 alkyl, substituted Ci-C 6 alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfo, sulfonic acid ester, azido, carboxy, substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted C 3 -C 8 cycloalkyl,
  • each A and B is independently CR 2a R 2b ;
  • W and Z are independently N or CR 4 ;
  • L 1 is a single bond or substituted or unsubstituted Ci-C 5 alkylene
  • R 1 is selected from a substituted or unsubstituted aryl or heteroaryl; each of R 2a , and R 2b is independently selected from hydrogen, and substituted or unsubstituted Q-
  • R 3 is selected from substituted or unsubstituted Ci-C 6 alkyl, substituted or unsubstituted C 3 -
  • R 4 is independently selected from H, Ci-C ⁇ alkyl, substituted Ci-C ⁇ alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfo, sulfonic acid ester, azido, carboxy, substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted Cs-Cgcycloalkyl, substituted
  • A is CR 2a R 2b .
  • A is CHR 2b .
  • A is CH 2 .
  • B is CR 2a R 2b . In another embodiment, B is CHR 2b .
  • B is CH 2 .
  • B is CH 2 .
  • R 1 is substituted or unsubstituted aryl.
  • R 1 is substituted or unsubstituted phenyl.
  • R 1 is substituted or unsubstituted heteroaryl.
  • R 1 is substituted or unsubstituted pyridyl.
  • R 1 is unsubstituted phenyl. In another embodiment, R 1 is unsubstituted pyridyl.
  • R 1 is phenyl, pyridyl or quinolin-3-yl, substituted with one or more substituents independently selected from halo, Ci-C ⁇ alkyl, haloCi-C ⁇ alkyl, CrCgcycloalkyl, amino, aryl, heteroaryl, cyano, hydroxy, alkoxy and substituted sulfonyl.
  • R 1 is phenyl, pyridyl or quinolin-3-yl, substituted with one or more substituents independently selected from Me, Et, Ph, Cl, F,
  • each A and B is independently CR 2a R 2b ;
  • W and Z are independently N or CR 4 ;
  • L 1 is a single bond or substituted or unsubstituted C r C 5 alkylene, -CO-, -NHC(O)-, -OC(O)-,-SO-
  • R 1 is selected from a substituted or unsubstituted bicycloaryl or bicycloheteroaryl; each of R 2a , and R 2b is independently selected from hydrogen, and substituted or unsubstituted Ci-
  • R is selected from substituted or unsubstituted Ci-C ⁇ alkyl, substituted or unsubstituted C 3 -
  • R 4 is independently selected from H, Ci-C ⁇ alkyl, substituted Ci-C ⁇ alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, substituted arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfo, sulfonic acid ester, azido, carboxy
  • R 1 is substituted or unsubstituted naphthylene.
  • R 1 is substituted or unsubstituted bicycloheteroaryl.
  • R 1 is substituted or unsubstituted quinoline.
  • R 1 is substituted or unsubstituted isoquinoline.
  • R 1 is selected from substituted or unsubstituted benzodioxole, substituted or unsubstituted benzodioxane, substituted or unsubstituted benzofuran, substituted or unsubstituted benzothiophene, and substituted or unsubstituted benzodioxepine.
  • R 1 is substituted or unsubstituted quinolin-3-yl.
  • R 1 is unsubstituted quinolin-3-yl.
  • L 1 is a single bond.
  • L 1 is a Ci-C 5 alkylene group.
  • L 1 is -CH 2 -, -C(Me)H-
  • L 1 is -CO-, -NHC(O)-
  • L 1 is -SO-.
  • L 1 is -S(O) 2 -.
  • W is CR 4 and R 4 is H, substituted or unsubstituted Ci-C ⁇ alkyl, or halo. [[0000119966]] IInn oomne particular embodiment, with respect to compounds of formula I, W is CR 4 and R 4 is H,
  • Z is CR 4 and R 4 is H, substituted or unsubstituted Ci-C ⁇ alkyl, or halo.
  • Z is CR 4 and R 4 is H
  • each of W and Z is independently CH.
  • W is N, and Z is CH.
  • the compound is according to formula Ha, lib, Hc, Hd, He, Hf, Hg, Hh, Iii, or Hj:
  • the compound is according to formula Ha, lib, Hc, Hd, He or Hf:
  • the compound is according to formula Ha, lib, Hc, Hd, He, or Hf.
  • R 3 is substituted or unsubstituted Ci-C ⁇ alkyl.
  • R 3 is unsubstituted Ci-C 6 alkyl.
  • R 3 is Me, Et, n-Pr, i-Pr, n-Bu, t-Bu, 1 -methylpropyl, 2-methylpropyl, 2,2-dimethylpropyl, or CF 3 .
  • R 3 is Ci-C 6 alkyl, substituted with halo, hydroxy or alkoxy. In another embodiment, R 3 is Ci-C 6 alkyl, substituted with Cl, F or OH. [00209] In one particular embodiment, with respect to compounds of formula I-IIf, R 3 is CH 2 OH.
  • R is CH 2 Ph.
  • R 3 is CH 2 -(2-Cl-Ph).
  • R 3 is CH 2 -
  • R 3 is C 3 -
  • R is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • R is unsubstituted cyclobutyl.
  • R 3 is unsubstituted cyclopentyl.
  • R 3 is unsubstituted cyclohexyl.
  • R 3 is unsubstituted cyclobutyl.
  • R 3 is unsubstituted cyclohexyl.
  • R 3 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, substituted with one or more substituents independently selected from halo, hydroxyl, Ci-C ⁇ alkyl, alkoxy and haloalkyl.
  • R is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, substituted with one or more substituents independently selected from Me, Et, Cl, F, CN, OH, OMe, OEt, CF 3 , CHF 2 , OCF 3 , i-Pr, i-Bu, and t-Bu.
  • R 3 is substituted or unsubstituted heterocycloalkyl.
  • R 3 is unsubstituted pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, or piperazinyl.
  • R 3 is pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, or piperazinyl, substituted with one or more substituents independently selected from halo, hydroxyl, Ci-C 6 alkyl, alkoxy and haloCi-C 6 alkyl.
  • R 3 is pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl, substituted with one or more substituents independently selected from Me, Et, Cl, F, CN, OH, OMe, OEt, CF 3 , CHF 2 , OCF 3 , i-Pr, i-Bu, and t-Bu.
  • R is pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl, substituted with Me.
  • R is pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl, unsubstituted or substituted with Me.
  • R is substituted or unsubstituted aryl or heteroaryl.
  • R is phenyl, unsubstituted or substituted with one or more substituents independently selected from halo, hydroxyl, amino, cyano, sulfo, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, amido, carboxy, Ci -Ce alkoxycarbonyl, Ci-C 6 alkyl, substituted Ci-C 6 alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, and sulfonamide.
  • R 3 is monosubstituted phenyl.
  • R 3 is disubstituted phenyl.
  • R 3 is Ph, 2-Cl-Ph, 2-F-Ph, 4-Cl-Ph, 4-F-Ph, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-0H-Ph, or 2-0H-Ph.
  • R is Ph substituted with substituted or unsubstituted amino.
  • R 3 is Ph substituted with NH 2 .
  • R 3 is Ph, 2-Cl-Ph, 2-F-Ph, 4-Cl-Ph, 4-F-Ph, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-0H-Ph, or 2-0H-Ph. In another particular embodiment, R 3 is 4-0H-Ph.
  • R is Ph substituted with Cl.
  • R 3 is 2-Cl-Ph, 3 -Cl-Ph, or 4-Cl-Ph.
  • R is 2-Cl-Ph.
  • R 3 is Ph substituted with F.
  • R is 2-F-Ph, 3-F-Ph, or 4-F-Ph.
  • R 3 is 2-F-Ph.
  • R is Ph substituted with OCF 3 .
  • R 3 is 3-OCF 3 -Ph.
  • R 3 is 2-OCF 3 -Ph.
  • R 3 is Ph substituted with CF 3 .
  • R 3 is 3-CF 3 -Ph.
  • R 3 is 2-CF 3 -Ph or 4-CF 3 -Ph.
  • R 3 is 2,4- difluorophenyl.
  • R 3 is Ph substituted with NO 2 .
  • R 3 is 2-NO 2 -Ph, 3-NO 2 -Ph, or 4-NO 2 -Ph.
  • R 3 is 2-NO 2 Ph.
  • R 3 is 2,4-di-NO 2 Ph.
  • R is pyridyl, unsubstituted or substituted with one or more substituents independently selected from halo, hydroxyl, amino, cyano, sulfo, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, amido, carboxy, Ci -Ce alkoxycarbonyl, Ci-C 6 alkyl, substituted Ci-C 6 alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, and sulfonamide.
  • R is unsubstituted pyrimidinyl, quinolinyl, isoquinolinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, benzoxazinyl, benzdioxolanyl, pyrrolyl, furanyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thienyl, thiazolyl, oxadiazolyl, or thiadiazolyl.
  • R 3 is unsubstituted indolyl, indazolyl, thiadiazolyl, or furanyl.
  • R 3 is pyrimidinyl, quinolinyl, isoquinolinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, benzoxazinyl, benzdioxolanyl, pyrrolyl, furanyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thienyl, thiazolyl, oxadiazolyl, or thiadiazolyl, substituted with one or more substituents independently selected from halo, hydroxyl, amino, cyano, sulfo, substituted sulfonyl, substituted sulfanyl, amido, carboxy, Ci-C 6 alkoxycarbonyl, Ci-C ⁇ alkyl, substituted Ci-C ⁇ alkyl, alkenyl, substituted alkenyl, alkynyl
  • R is pyrimidinyl, quinolinyl, isoquinolinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, benzoxazinyl, benzdioxolanyl, pyrrolyl, furanyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thienyl, thiazolyl, oxadiazolyl, or thiadiazolyl, substituted with one or more substituents independently selected from Me,
  • CH CH-CO 2 H, SOMe, SO 2 Me, SO 3 H, SO 3 Me, and pyridyl.
  • R is unsubstituted thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, or oxadiazolyl.
  • R 3 is thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, or oxadiazolyl, substituted with one or more substituents independently selected from Me, Et, Cl, CF 3 , CO 2 Me, CO 2 Et, and NHAc.
  • R 3 is Ph, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, or oxadiazolyl, substituted with 5- membered heteroaryl.
  • the 5-membered heteroaryl is selected from pyrrolyl, thiopheny, oxazolyl, pyrazolyl, thiazolyl, and thiadiazolyl.
  • the 5- membered heteroaryl substituted with halo or Ci-Ce alkyl.
  • the 5- membered heteroaryl is selected from pyrrolyl, thiopheny, oxazolyl, pyrazolyl, thiazolyl, and thiadiazolyl, substituted with one or more substituents independently selected from Me, Et, Cl, and CF 3 .
  • R 3 is thiophenyl, methylthiophenyl, furanyl, methylfuranyl, pyrazolyl, or methylpyrazolyl.
  • R 3 is thiadiazolyl substituted with Me, Et, Cl, or CF 3 .
  • R is thiadiazolyl substituted with
  • R 3 is 1 ,2,4-thiadiazolyl.
  • R is oxadiazolyl substituted with Me, Et, Cl, CO 2 Et, or CF 3 .
  • R 3 is oxadiazolyl substituted with CO 2 Et.
  • R is 1 ,2,4-oxadiazolyl.
  • R is furanyl, unsubstitured or substituted with Me, Et, Cl, or CF 3 .
  • R 3 is unsubstituted furanyl.
  • R is furanyl substituted with Cl.
  • R 3 is thiophenyl, unsubstitured or substituted with Me, Et, Cl, CO 2 Et, or CF 3 .
  • R 3 is unsubstituted thiophenyl.
  • R 3 is thiophenyl substituted with Cl or
  • R is oxazoyl or thiazolyl, unsubstitured or substituted with Me, Et, Cl, or CF 3 .
  • R 3 is unsubstituted thiazolyl.
  • R is thiazoyl substituted with Me or Cl.
  • R 3 is thiazoyl or oxazolyl substituted with dimethyl.
  • R is pyrazolyl substituted with Me, Et, Cl, CO 2 Et, or CF 3 .
  • R 3 is pyrazolyl substituted with CO 2 Et or Me.
  • R 3 is thiophenyl, methylthiophenyl, furanyl, methylfuranyl, pyrazolyl, or methylpyrazolyl, substituted with one or more substituents independently selected from Me, Et, Cl, CF 3 , CO 2 Me, CO 2 Et, and NHAc.
  • R is thiazolyl, pyridyl, cyclohexyl, phenyl, cyclopentyl, tetrahydrothiopyranyl, pyrazolyl, tetrahydropyranyl, unsubstituted or substituted with one or two Me.
  • R 3 is unsubstituted thiazolyl, pyridyl, cyclohexyl, phenyl, cyclopentyl, tetrahydrothiopyranyl, pyrazolyl, tetrahydropyranyl.
  • R 3 is thiazolyl, pyridyl, phenyl, or pyrazolyl, substituted with Me.
  • R 3 is thiazolyl, or pyrazolyl, substituted with diMe.
  • R is dimethylthiazolyl, or dimethylpyrazolyl.
  • the compound is according to formula Hg or Hh:
  • the compound is according to formula Hg.
  • the compound is according to formula Hh.
  • the compound is according to formula Hi.
  • the compound is according to formula Hj.
  • R 3 is substituted or unsubstituted Ci-C ⁇ alkyl.
  • R 3 is unsubstituted Ci-C ⁇ alkyl.
  • R 3 is Ci-C ⁇ alkyl, substituted with halo, hydroxy or alkoxy.
  • R is Ci-C ⁇ alkyl, substituted with Cl, F or OH.
  • R is CH 2 OH.
  • R 3 is CH 2 Ph.
  • R is CH 2 -(2-Cl-Ph).
  • R is CH 2 -
  • R is C 3 -
  • Cgcycloalkyl unsubstituted or substituted with one or more substituents independently selected from halo, hydroxyl, Ci-C 6 alkyl, alkoxy and haloalkyl.
  • R 3 is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • R 3 is unsubstituted cyclobutyl.
  • R is unsubstituted cyclopentyl.
  • R is unsubstituted cyclohexyl.
  • R is unsubstituted cyclobutyl.
  • R is unsubstituted cyclohexyl.
  • R is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, substituted with one or more substituents independently selected from halo, hydroxyl, Ci-C ⁇ alkyl, alkoxy and haloalkyl.
  • R is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, substituted with one or more substituents independently selected from Me, Et, Cl, F, CN, OH, OMe, OEt, CF 3 , CHF 2 , OCF 3 , i-Pr, i-Bu, and t-Bu.
  • R 3 is substituted or unsubstituted heterocycloalkyl.
  • R 3 is unsubstituted pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, or piperazinyl.
  • R is pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, or piperazinyl, substituted with one or more substituents independently selected from halo, hydroxyl, Ci-C ⁇ alkyl, alkoxy and haloCi-C ⁇ alkyl.
  • R 3 is pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl, substituted with one or more substituents independently selected from Me, Et, Cl, F, CN, OH, OMe, OEt, CF 3 , CHF 2 , OCF 3 , i-Pr, i-Bu, and t-Bu.
  • R is pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl, substituted with Me.
  • R is pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl, unsubstituted or substituted with Me.
  • R is substituted or unsubstituted aryl or heteroaryl.
  • R is phenyl, unsubstituted or substituted with one or more substituents independently selected from halo, hydroxyl, amino, cyano, sulfo, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, amido, carboxy, Ci-C 6 alkoxycarbonyl, Ci-C 6 alkyl, substituted Ci-C 6 alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, and sulfonamide.
  • R 3 is phenyl substituted with one or more substituents independently selected from Me, Et, Ph, Cl, F, Br, CN, OH,
  • R 3 is monosubstituted phenyl. In another embodiment R is disubstituted phenyl.
  • R 3 is Ph, 2-C1-
  • Ph 2-F-Ph, 4-Cl-Ph, 4-F-Ph, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-OH-Ph, or 2-OH-Ph.
  • R 3 is Ph substituted with substituted or unsubstituted amino. In another particular embodiment, R is Ph substituted with NH 2 .
  • R is Ph, 2-C1-
  • R is 4-OH-Ph.
  • R is Ph substituted with Cl.
  • R 3 is 2-Cl-Ph, 3 -Cl-Ph, or 4-Cl-Ph.
  • R is 2-Cl.
  • R 3 is Ph substituted with F.
  • R 3 is 2-F-Ph, 3-F-Ph, or 4-F-Ph.
  • R 3 is 2-F.
  • R 3 is Ph substituted with OCF 3 .
  • R is 3-OCF 3 -Ph.
  • R 3 is 2-OCF 3 -Ph.
  • R is Ph ssuubbssttiittuutteedd wwiitthh CCFF 33 .. IInn aannootthheerr pcuprttiiccuullaarr embodiment, R 3 is 3-CF 3 -Ph. In yet another particular embodiment, R 3 is 2-CF 3 -Ph or 4-CF 3 -Ph.
  • R 3 is 2,4- difluorophenyl.
  • R 3 is Ph substituted with NO 2 .
  • R 3 is 2-NO 2 -Ph, 3-NO 2 -Ph, or 4-NO 2 -Ph.
  • R 3 is 2-NO 2 Ph.
  • R 3 is 2,4-di-NO 2 Ph.
  • R is pyridyl, unsubstituted or substituted with one or more substituents independently selected from halo, hydroxyl, amino, cyano, sulfo, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, amido, carboxy, Ci-Ce alkoxycarbonyl, Ci-C 6 alkyl, substituted Ci-C 6 alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, and sulfonamide.
  • R 3 is pyridyl substituted with one or more substituents independently selected from Me, Et, Ph, Cl, F, Br, CN, OH,
  • R is unsubstituted pyrimidinyl, quinolinyl, isoquinolinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, benzoxazinyl, benzdioxolanyl, pyrrolyl, furanyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thienyl, thiazolyl, oxadiazolyl, or thiadiazolyl.
  • R is unsubstituted indolyl, indazolyl, thiadiazolyl, or furanyl.
  • R is pyrimidinyl, quinolinyl, isoquinolinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, benzoxazinyl, benzdioxolanyl, pyrrolyl, furanyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thienyl, thiazolyl, oxadiazolyl, or thiadiazolyl, substituted with one or more substituents independently selected from halo, hydroxyl, amino, cyano, sulfo, substituted sulfonyl, substituted sulfanyl, amido, carboxy, Ci -C ⁇ alkoxycarbonyl, Ci-C 6 alkyl, substituted Ci-C 6 alkyl, alkenyl, substituted alkenyl, alkyn
  • R is pyrimidinyl, quinolinyl, isoquinolinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, benzoxazinyl, benzdioxolanyl, pyrrolyl, furanyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thienyl, thiazolyl, oxadiazolyl, or thiadiazolyl, substituted with one or more substituents independently selected from Me,
  • CH CH-CO 2 H, SOMe, SO 2 Me, SO 3 H, SO 3 Me, and pyridyl.
  • R 3 is unsubstituted thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, or oxadiazolyl.
  • R 3 is thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, or oxadiazolyl, substituted with one or more substituents independently selected from Me, Et, Cl, CF 3 , CO 2 Me, CO 2 Et, and NHAc.
  • R is Ph, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, thiadiazolyl, or oxadiazolyl, substituted with 5- membered heteroaryl.
  • the 5-membered heteroaryl is selected from pyrrolyl, thiopheny, oxazolyl, pyrazolyl, thiazolyl, and thiadiazolyl.
  • the 5- membered heteroaryl substituted with halo or Ci-Ce alkyl.
  • the 5- membered heteroaryl is selected from pyrrolyl, thiopheny, oxazolyl, pyrazolyl, thiazolyl, and thiadiazolyl, substituted with one or more substituents independently selected from Me, Et, Cl, and CF 3 .
  • R 3 is thiophenyl, methylthiophenyl, furanyl, methylfuranyl, pyrazolyl, or methylpyrazolyl.
  • R 3 is thiadiazolyl substituted with Me, Et, Cl, or CF 3 . In another particular embodiment, R 3 is thiadiazolyl substituted with
  • R 3 is 1 ,2,4-thiadiazolyl.
  • R 3 is oxadiazolyl substituted with Me, Et, Cl, CO 2 Et, or CF 3 .
  • R 3 is oxadiazolyl substituted with CO 2 Et.
  • R 3 is 1 ,2,4-oxadiazolyl.
  • R is furanyl, uunnssuubbssttiittuurreedd oorr ssuubbssttiittuutteedd wwiitthh MMee,, EEtt,, CCll,, oorr CCFF 33 .
  • IInn aannootthheerr pcuprttiiccuullaarr eemmbbooddiiment R 3 is unsubstituted furanyl.
  • R is furanyl substituted with Cl.
  • R 3 is thiophenyl, unsubstitured or substituted with Me, Et, Cl, CO 2 Et, or CF 3 .
  • R is uunnssuubbssttituted thiophenyl.
  • R 3 is thiophenyl substituted with Cl or
  • R 3 is oxazoyl or thiazolyl, unsubstitured or substituted with Me, Et, Cl, or CF 3 .
  • R is uunnssuubbssttiittuutteedd tthhiiaazzoollyyll..
  • R is thiazoyl or oxazolyl substituted with dimethyl.
  • R is pyrazolyl substituted with Me, Et, Cl, CO 2 Et, or CF 3 .
  • R 3 is pyrazolyl substituted with CO 2 Et or Me.
  • R 3 is thiophenyl, methylthiophenyl, furanyl, methylfuranyl, pyrazolyl, or methylpyrazolyl, substituted with one or more substituents independently selected from Me, Et, Cl, CF 3 , CO 2 Me, CO 2 Et, and NHAc.
  • R 3 is thiazolyl, pyridyl, cyclohexyl, phenyl, cyclopentyl, tetrahydrothiopyranyl, pyrazolyl, tetrahydropyranyl, unsubstituted or substituted with one or two Me.
  • R is unsubstituted thiazolyl, pyridyl, cyclohexyl, phenyl, cyclopentyl, tetrahydrothiopyranyl, pyrazolyl, tetrahydropyranyl.
  • R 3 is thiazolyl, pyridyl, phenyl, or pyrazolyl, substituted with Me.
  • R 3 is thiazolyl, or pyrazolyl, substituted with diMe.
  • R 3 is dimethylthiazolyl, or dimethylpyrazolyl.
  • R 3 is a phenyl. In certain embodiments, R 3 is a substituted phenyl.
  • R is a mono-substituted phenyl.
  • R 3 is a di-substituted phenyl.
  • R 3 is a substituted phenyl where the substituent on the phenyl is selected from halo, amido, Ci-C 6 alkyl, alkoxy, sulfonyl, sulfonamidyl, haloalkyl and trihaloalkyl.
  • the substitution on the R 3 phenyl is selected from Cl, F, CF 3 , Me, t-Bu, OMe,
  • the substitution on the R 3 phenyl is selected from Cl, Me, t-Bu and SO 2 Me.
  • R is a substituted phenyl
  • one or more substituents are on the phenyl at the 2 (ortho), 3 (meta) and/or 4 (para) position relative to the carbon attached to the nitrogen atom in the fused heterocyclic scaffold in formula I.
  • R is a substituted phenyl, where a substituent is on the phenyl at the 2 (ortho), 3 (meta) and/or 4 (para) position.
  • the substitution on the R phenyl is at the 2 or 4 position.
  • the substitution on the R 3 phenyl is at the 4 position.
  • R are selected from
  • n' is selected from 1-5 and each of R 5 is independently selected from H, Ci-C ⁇ alkyl, substituted Ci-C ⁇ alkyl, acyl, substituted acyl, substituted or unsubstituted acylamino, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, alkoxycarbonyl, substituted alkoxycarbonyl arylalkyloxy, substituted arylalkyloxy, amino, aryl, substituted aryl, arylalkyl, substituted arylalkyl, substituted arylalkyl, substituted sulfanyl, substituted sulfinyl, substituted sulfonyl, substituted or unsubstituted aminosulfonyl, sulfo, sulfonic acid ester, azido, carboxy, substituted or unsubstituted carbamoyl, cyano, substituted or unsubstituted C 3
  • subscript n' is 1, 2 or 3.
  • subscript n' is 1 or 2.
  • each R 5 is independently selected from Me, Et, Pr, iso-Pr, Ph, Cl, F,
  • each R 5 is independently selected from Me, Et, Pr, iso-Pr, Ph, Cl, F,
  • the compound is according to formula Ilia, HIb, UIc, IHd, IHe, IHf, IHg, IHh or IHi:
  • L 1 is a single bond, -CH 2 -, -CO-, -NHC(O)-, -OC(O)-, or S(O) 2 ; and R 3a is H, alkyl, alkoxy, halo, haloalkyl, thioalkyl, or haloalkyloxy; and R 3b is H or alkyl.
  • the compound is according to formula Ilia or IHb.
  • the compound is according to formula IHc.
  • the compound is according to formula IHd.
  • the compound is according to formula IHe.
  • the compound is according to formula IHf.
  • the compound is according to formula IHh.
  • the compound is according to formula IHi.
  • R 3a is H, Me
  • R 3a is H.
  • R 3b is H, Me
  • R 3b is H.
  • L 1 is a single bond or -CH 2 -.
  • L 1 is a single bond.
  • L 1 is -CH 2 -.
  • L 1 is -CO-, -
  • L 1 is -CO-, -
  • L 1 is -S(O) 2 -.
  • the compound is according to formula IVa, IVb, IVc, IVd, IVe, IVf, IVg, IVh or IVi:
  • R > 3 3 a a is H, alkyl, alkoxy, halo, haloalkyl, thioalkyl, or haloalkyloxy; and R 3b is H or alkyl.
  • the compound is according to formula Va, Vb, Vc, Vd, Ve, Vf, Vg, Vh or Vi:
  • R 3a is H, alkyl, alkoxy, halo, haloalkyl, thioalkyl, or haloalkyloxy; and R 3b is H or alkyl.
  • R 3a is H, Me, Et, OMe, CF 3 , OCF 3 , OCF 2 , SMe, Cl, or F.
  • R 3a is H.
  • R 3b is H, Me,
  • R 3b is H.
  • R 3b is H
  • the compound is selected from the compounds listed in Table 1.
  • the compound is selected from:
  • the compound is selected from:
  • the present invention provides prodrugs and derivatives of the compounds according to the formulae above.
  • Prodrugs are derivatives of the compounds of the invention, which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention, which are pharmaceutically active, in vivo.
  • Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholinyl esters and the like.
  • Certain compounds of this invention have activity in both their acid and acid derivative forms, but the acid sensitive form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
  • Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are preferred prodrugs.
  • double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
  • the compounds of this invention are typically administered in the form of a pharmaceutical composition.
  • Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.
  • the pharmaceutical composition may comprise a compound of the invention in combination with one or more compounds or compositions of like therapeutic utility and effect.
  • the compounds of this invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound -administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • compositions of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal.
  • the compounds of this invention are preferably formulated as either injectable or oral compositions or as salves, as lotions or as patches all for transdermal administration.
  • the compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions.
  • the furansulfonic acid compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
  • Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like.
  • Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • Injectable compositions are typically based upon injectable sterile saline or phosphate- buffered saline or other injectable carriers known in the art.
  • the active compound in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
  • Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight.
  • the active ingredients When formulated as a ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example an oil-in-water cream base.
  • Such transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration of stability of the active ingredients or the formulation.
  • transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.
  • the compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems.
  • sustained release materials can be found in Remington's Pharmaceutical Sciences.
  • a compound of the invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1 :2 weight ratio.
  • a minor amount of magnesium stearate may be added as a lubricant.
  • the mixture is formed into 240-270 mg tablets (80-90 mg of active compound per tablet) in a tablet press.
  • a compound of the invention may be admixed as a dry powder with a starch diluent in an approximate 1 : 1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active compound per capsule).
  • a compound of the invention (125 mg) may be admixed with sucrose (1.75 g) and xanthan gum (4 mg) and the resultant mixture may be blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11 :89, 50 mg) in water.
  • Sodium benzoate (10 mg) flavor, and color are diluted with water and added with stirring. Sufficient water may then added to produce a total volume of 5 mL.
  • a compound of the invention may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
  • a minor amount of magnesium stearate is added as a lubricant.
  • the mixture is formed into 450-900 mg tablets (150-300 mg of active compound) in a tablet press.
  • a compound of the invention may be dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/mL.
  • Stearyl alcohol (250 g) and a white petrolatum (250 g) may be melted at about 75°C and then a mixture of a compound of the invention (50 g) methylparaben (0.25 g), propylparaben (0.15 g), sodium lauryl sulfate (10 g), and propylene glycol (120 g) dissolved in water (about 370 g) may be added and the resulting mixture is stirred until it congeals.
  • the present compounds are used as therapeutic agents for the treatment of conditions in mammals. Accordingly, the compounds and pharmaceutical compositions of this invention find use as therapeutics for preventing and/or treating neurodegenerative, autoimmune and inflammatory conditions in mammals including humans. Thus, and as stated earlier, the present invention includes within its scope, and extends to, the recited methods of treatment, as well as to the compounds for use in such methods, and for the preparation of medicaments useful for such methods.
  • this invention provides a method of treating a mammal susceptible to or afflicted with a condition associated with arthritis, asthma, dermatitis, myocardial infarction, inflammatory bowel disease and autoimmune disorders, which method comprises administering an effective amount of one or more of the pharmaceutical compositions just described.
  • this invention provides methods of treating a mammal susceptible to or afflicted with neurodegenerative diseases and disorders such as, for example Parkinson's disease, Alzheimer's disease and multiple sclerosis; sleep disorders, anxiety and depression disorders, weight and eating disorders, addiction, spasticity, and glaucoma; diseases and disorders which are mediated by or result in neuroinflammation such as, for example encephalitis; centrally -mediated neuropsychiatric diseases and disorders such as, for example depression mania, bipolar disease, anxiety, schizophrenia, eating disorders, sleep disorders and cognition disorders; epilepsy and seizure disorders; prostate, bladder and bowel dysfunction such as, for example urinary incontinence, urinary hesitancy, rectal hypersensitivity, fecal incontinence, benign prostatic hypertrophy and inflammatory bowel disease; respiratory and airway disease and disorders such as, for example, allergic rhinitis, asthma and reactive airway disease and chronic obstructive pulmonary disease; diseases and disorders which are mediated
  • this invention provides a method of treating a mammal susceptible to or afflicted with a condition that gives rise to pain responses or that relates to imbalances in the maintenance of basal activity of sensory nerves.
  • the present compounds have use as analgesics for the treatment of pain of various geneses or etiology, for example acute, inflammatory pain (such as pain associated with osteoarthritis and rheumatoid arthritis); various neuropathic pain syndromes (such as post-herpetic neuralgia, trigeminal neuralgia, reflex sympathetic dystrophy, diabetic neuropathy, Guillian Barre syndrome, fibromyalgia, phantom limb pain, post-mastectomy pain, peripheral neuropathy, HIV neuropathy, and chemotherapy-induced and other iatrogenic neuropathies); visceral pain, (such as that associated with gastroesophageal reflex disease, irritable bowel syndrome, inflammatory bowel disease, pancreatitis, and various gy
  • the present compounds for use as a pharmaceutical especially in the treatment or prevention of the aforementioned conditions and diseases.
  • Injection dose levels range from about 0.1 mg/kg/hour to at least 10 mg/kg/hour, all for from about 1 to about 120 hours and especially 24 to 96 hours.
  • a preloading bolus of from about 0.1 mg/kg to about 10 mg/kg or more may also be administered to achieve adequate steady state levels.
  • the maximum total dose is not expected to exceed about 2 g/day for a 40 to 80 kg human patient.
  • the regimen for treatment usually stretches over many months or years so oral dosing is preferred for patient convenience and tolerance. With oral dosing, one to five and especially two to four and typically three oral doses per day are representative regimens.
  • each dose provides from about 0.01 to about 20 mg/kg of the compound of the invention, with preferred doses each providing from about 0.1 to about 10 mg/kg and especially about 1 to about 5 mg/kg.
  • Transdermal doses are generally selected to provide similar or lower blood levels than are achieved using injection doses.
  • the compounds of this invention When used to prevent the onset of a neurodegenerative, autoimmune or inflammatory condition, the compounds of this invention will be administered to a patient at risk for developing the condition, typically on the advice and under the supervision of a physician, at the dosage levels described above.
  • Patients at risk for developing a particular condition generally include those that have a family history of the condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the condition.
  • the compounds of this invention can be administered as the sole active agent or they can be administered in combination with other agents, including other active amines and derivatives.
  • the compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. See, e.g., Synthetic Scheme, below. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. [00386] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
  • the choice of a suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in T. W. Greene and P. G. M. Wuts, Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein.
  • the compounds of this invention may be prepared by the reaction of a chloro derivative with an appropriately substituted amine and the product isolated and purified by known standard procedures. Such procedures include (but are not limited to) recrystallization, column chromatography or HPLC. The following schemes are presented with details as to the preparation of representative fused heterocyclics that have been listed hereinabove.
  • the compounds of the invention may be prepared from known or commercially available starting materials and reagents by one skilled in the art of organic synthesis. [00388]
  • the compounds of the present invention may be prepared by a variety of processes well known for the preparation of compounds of this type, for example reaction schemes, and general procedures as described below.
  • reaction could be conducted using EtOH as solvent and heating under microwave irradiation (in a sealed vial) at 125°C for about 2hr.
  • the flask was purged first with nitrogen, then with argon, whereupon argon-sparged Toluene (50 mL, 500 mmol) was added.
  • the resulting red slurry was heated to IOOC in an oil bath (start 11 :15). After 10 min, additional Toluene (40 mL) was added to improve stirrability. Aliquot after 22 h: LCMS showed the reaction was complete.
  • the light orange slurry was diluted with water (100 mL) and EtOAc (100 mL) and extracted with 1 M H 3 PO 4 (100 mL, 2 x 40 mL).
  • the aqueous filtrate was basified to pH 10 with 6 M NaOH, and extracted with CHCl 3 (2 x 100 mL).
  • the filter cake (primarily phosphate salt of the desired product) was stirred with a mixture of 1 M NaOH (200 mL) and DCM (200 mL), and the aqueous phase extracted with DCM (100 mL).
  • the combined CHCl 3 and DCM extracts were dried (Na 2 SO 4 ), filtered through celite and concentrated to an orange solid (4.98 g), which was absorbed on silica (13 g).
  • N,N-Diisopropylethylamine 35 uL, 0.20 mmol was added to a suspension of (6,7-dihydro- 5H-pyrrolo[3,4-d]pyrimidin-4-yl)-quinolin-3-yl-amine dihydrochloride (17 mg, 0.050 mmol), 2,4- dimethyl-thiazole-5-carboxylic acid (9.4 mg, 0.060 mmol), and N,N,N',N'-tetramethyl-O-(7- azabenzotriazol- 1 -yl)uronium hexafluorophosphate (28 mg, 0.075 mmol) in N-methylpyrrolidinone (400 uL, 4 mmol) in a 1.5 mL vial, and the mixture was stirred at room temperature.
  • reaction mixture was quenched with N-ethylethanamine (18.46 uL, 0.1784 mmol). After filtering, the reaction mixture was injected directly onto a reversed-phase HPLC (acetonitrile -water at pHIO) and the purified product was isolated, giving [6-(5-oxazol-5-yl-thiophene-2-sulfonyl)-6,7-dihydro-5H- pyrrolo [3, 4-d]pyrimidin-4-yl]-quinolin-3 -yl-amine (3 mg) as a white solid. Purity was found to be 99.5% by analytical HPLC.
  • reaction mixture was quenched with N- ethylethanamine (18.46 uL, 0.1784 mmol). After filtering, the reaction mixture was injected directly onto a reversed-phase HPLC (acetonitrile-water at pHIO) and the purified product was isolated, giving [6-(2,4- difluoro-benzenesulfonyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl]-quinolin-3-yl-amine (5 mg) as a white solid. Purity was 98.7% by analytical HPLC.
  • reaction mixture was quenched with N-ethylethanamine (18.46 uL, 0.1784 mmol). After filtering, the reaction mixture was injected directly onto a reversed-phase HPLC (acetonitrile -water at pHIO) and the purified product was isolated, giving 476-22-1 (4 mg) as a white solid. Purity was 97.0% by analytical HPLC.
  • reaction mixture was injected directly onto a reversed-phase HPLC (acetonitrile-water at pHIO) and the purified product was isolated, giving [6-(2,4- dimethyl-thiazole-5-sulfonyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl]-quinolin-3-yl-amine (7 mg) as a white solid. Purity was 97.6% by analytical HPLC.

Abstract

La présente invention concerne des composés de formule I, dans laquelle A, B, L1, W, Y, R1 et R3 sont tels que définis. Ces composés et leurs compositions pharmaceutiques sont utiles dans la prévention et le traitement de divers états chez les mammifères, notamment les humains, notamment et de manière non restrictive, la douleur, l’anxiété, la dépression, l'inflammation, les troubles cognitifs, les troubles du poids et de l'alimentation, la maladie de Parkinson, la maladie d'Alzheimer, la spasticité, la dépendance et le glaucome.
PCT/US2009/064757 2008-11-19 2009-11-17 Composés 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine s'utilisant comme modulateurs de la faah et utilisations desdits composés WO2010059610A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2011537547A JP5539376B2 (ja) 2008-11-19 2009-11-17 Ｆａａｈ調整因子として有用な６，７−ジヒドロ−５ｈ−ピロロ［３，４−ｄ］ピリミジン−４−イル］キノリン−３−イルアミン化合物およびその使用
CA2744343A CA2744343A1 (fr) 2008-11-19 2009-11-17 Composes 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine s'utilisant comme modulateurs de la faah et utilisations desdits composes
EP09793640A EP2364316A1 (fr) 2008-11-19 2009-11-17 Composés 6, 7 -dihydro- 5h- pyrrolo [3, 4-d¨pyrimidin-4-yl]-quinolin-3 -ylamine s'utilisant comme modulateurs de la faah et utilisations desdits composés
US13/130,051 US20110257208A1 (en) 2008-11-19 2009-11-17 Compounds useful as faah modulators and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11629208P 2008-11-19 2008-11-19
US61/116,292 2008-11-19
US13960008P 2008-12-20 2008-12-20
US61/139,600 2008-12-20

Publications (1)

Publication Number Publication Date
WO2010059610A1 true WO2010059610A1 (fr) 2010-05-27

Family

ID=41786362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/064757 WO2010059610A1 (fr) 2008-11-19 2009-11-17 Composés 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine s'utilisant comme modulateurs de la faah et utilisations desdits composés

Country Status (5)

Country Link
US (1) US20110257208A1 (fr)
EP (1) EP2364316A1 (fr)
JP (1) JP5539376B2 (fr)
CA (1) CA2744343A1 (fr)
WO (1) WO2010059610A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085216A2 (fr) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour traiter la maladie de parkinson et le syndrome des jambes sans repos
WO2011123719A2 (fr) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3089971T (pt) 2014-01-01 2020-09-03 Medivation Tech Llc Compostos e métodos de utilização

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032632A2 (fr) * 1999-11-01 2001-05-10 Eli Lilly And Company Composes pharmaceutiques
WO2008021456A2 (fr) * 2006-08-16 2008-02-21 Cytovia, Inc. N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose, et leurs utilisations
WO2008099210A2 (fr) * 2007-02-12 2008-08-21 Merck & Co., Inc. Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
WO2009011904A1 (fr) * 2007-07-19 2009-01-22 Renovis, Inc. Composés utiles comme modulateurs de la faah et utilisation de ceux-ci

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4922539B2 (ja) * 2000-09-15 2012-04-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
TW201018693A (en) * 2008-09-30 2010-05-16 Astrazeneca Ab Chemical compounds 496-1p

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032632A2 (fr) * 1999-11-01 2001-05-10 Eli Lilly And Company Composes pharmaceutiques
WO2008021456A2 (fr) * 2006-08-16 2008-02-21 Cytovia, Inc. N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose, et leurs utilisations
WO2008099210A2 (fr) * 2007-02-12 2008-08-21 Merck & Co., Inc. Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées
WO2009011904A1 (fr) * 2007-07-19 2009-01-22 Renovis, Inc. Composés utiles comme modulateurs de la faah et utilisation de ceux-ci

Non-Patent Citations (51)

* Cited by examiner, † Cited by third party
Title
"Remington's The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
A. C. KREITZER; R. C. MALENKA, NATURE, vol. 445, 2007, pages 643 - 647
A. H. LICHTMAN ET AL., J. PHARMACOL. EXP. THER., vol. 302, 2002, pages 73 - 79
A. JAYAMANNE ET AL., BR. J. PHARMACOL., vol. 147, 2005, pages 281 - 288
A. SAGHATELIAN ET AL., BIOCHEM., vol. 43, 2004, pages 14332 - 14339
B. F. CRAVATT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 98, 2001, pages 9371 - 9376
BAKER, D ET AL., NATURE, vol. 404, 2000, pages 84 - 87
BENNETT; XIE, PAIN, vol. 33, 1988, pages 87 - 107
CHAKI, S. ET AL., J PHARMACOL. EXP. THER., vol. 304, 2003, pages 818 - 826
CHAKI, S. ET AL., J. PHARMACOL. EXP. THER., vol. 304, 2003, pages 818 - 826
CHAPLAN ET AL., J NEUROSCI. METHODS, vol. 53, 1994, pages 55 - 63
D. L. BOGER ET AL., J. MED. CHEM., vol. 48, 2005, pages 1849 - 1856
DE HAAN, W. ET AL., ATHEROSCLEROSIS, vol. 197, 2008, pages 57 - 63
DETKE, M.J. ET AL., PSYCHOPHARMACOLOGY, vol. 121, 1995, pages 66 - 72
DIXON, ANN. REV. PHARMACOL. TOXICOL., vol. 20, 1980, pages 441 - 462
DUBUISSON; DENNIS, PAIN, vol. 4, 1977, pages 161 - 174
E. A. THOMAS ET AL., J NEUROSCI. RES., vol. 50, 1997, pages 1047 - 1052
G. GOBBI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 18620 - 18625
GRIEBEL, G. ET AL., J PHARMACOL. EXP. THER., vol. 301, 2002, pages 333 - 345
HARGREAVES ET AL., PAIN, vol. 32, 1988, pages 77 - 88
HOLT, S. ET AL., BRITISH JOURNAL OF PHARMACOLOGY, vol. 146, 2005, pages 467 - 476
HUGES, Z.A. ET AL., NEUROPHARMACOLOGY, vol. 54, 2008, pages 1136 - 1142
K. L. KAGE ET AL., J. NEUROSCI. METHODS, 1 November 2006 (2006-11-01)
KIM; CHUNG, PAIN, vol. 50, 1992, pages 355 - 363
KIMBALL, E.S. ET AL., AM. J PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 291, 2006, pages G364 - G371
KIMBALL, E.S. ET AL., AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 288, 2005, pages G1266 - G1273
KOTINEN ET AL., PAIN, vol. 80, 1999, pages 341 - 346
L. BOLDRUP ET AL., J. BIOCHEM. BIOPHYS. METHODS, vol. 60, 2004, pages 171 - 177
L. CHANG ET AL., BR. J PHARMACOL., vol. 148, 2006, pages 102 - 113
LAINE, K. ET AL., INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 43, 2002, pages 3216 - 3222
LIGRESTI, A. ET AL., BR. J PHARMACOL., vol. 147, 2006, pages 83 - 91
M. D. JHAVERI ET AL., J. NEUROSCI., vol. 26, 2006, pages 13318 - 13327
M. K. MCKINNEY; B. J. CRAVATT, ANNU. REV. BIOCHEM., vol. 74, 2005, pages 411 - 432
M. MACCARRONE ET AL., MOL. HUM. REPROD., vol. 10, 2004, pages 215 - 221
M. MOR ET AL., J. MED CHEM., vol. 47, 2004, pages 4998 - 5008
MCCALL ET AL., J PHARMACOL. EXP. THER., vol. 314, no. 3, 2005, pages 1248 - 1256
MEAD, R.J. ET AL., J IMMUNOLOGY, vol. 168, 2002, pages 458 - 465
MOR M ET AL: "Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 47, no. 21, 2 September 2004 (2004-09-02), pages 4998 - 5008, XP002386388, ISSN: 0022-2623 *
NUCCI, C. ET AL., INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 48, 2007, pages 2997 - 3004
POLOMANO ET AL., PAIN, vol. 94, 2001, pages 293 - 304
ROCK, E. M. ET AL., PSYCHOPHARMACOLOGY, vol. 196, 2008, pages 389 - 395
S. HOLT ET AL., BR. J PHARMACOL., vol. 146, 2005, pages 467 - 476
S. KATHURIA ET AL., NAT. MED., vol. 9, 2003, pages 76 - 81
S. WILSON ET AL., ANAL. BIOCHEM., vol. 318, 2003, pages 270 - 275
See also references of EP2364316A1 *
STEIN ET AL., PHARMACOL. BIOCHEM. BEHAV., vol. 31, 1988, pages 451 - 455
T. W. GREENE; P. G. M. WUTS: "Protecting Groups in Organic Synthesis", 1991, WILEY
VAN SICKLE M.D. ET AL., AM. J PHYSIOL. GASTROINTEST. LIVER PHYSIOL., vol. 285, 2003, pages G566 - G576
WALF, A.A.; FRYE, C.A., NATURE PROTOCOLS, vol. 2, 2007, pages 322 - 328
WESSELMAN, NEUROSCI. LETT., vol. 246, 1998, pages 73 - 76
WILEY, J.L. ET AL., BR. J PHARMACOL., vol. 145, 2005, pages 293 - 300

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085216A2 (fr) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour traiter la maladie de parkinson et le syndrome des jambes sans repos
WO2011123719A2 (fr) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes
WO2011123719A3 (fr) * 2010-03-31 2011-12-15 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour le traitement des douleurs abdominales, viscérales et pelviennes

Also Published As

Publication number Publication date
EP2364316A1 (fr) 2011-09-14
US20110257208A1 (en) 2011-10-20
JP5539376B2 (ja) 2014-07-02
JP2012509332A (ja) 2012-04-19
CA2744343A1 (fr) 2010-05-27

Similar Documents

Publication Publication Date Title
WO2009011904A1 (fr) Composés utiles comme modulateurs de la faah et utilisation de ceux-ci
JP7374955B2 (ja) 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法
TW202122388A (zh) Ｒｉｐ１抑制性化合物和用於製備和使用其之方法
TW202120488A (zh) 作為shp2抑制劑的化合物及其應用
AU2017382360A1 (en) Compounds, compositions and methods of use
AU2017278102B2 (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
WO2010039186A2 (fr) Composés utiles en tant que modulateurs de la faah et leurs utilisations
WO2010130638A1 (fr) Composés sulfamides, compositions pharmaceutiques et leurs utilisations
BR112015000790B1 (pt) Derivados de imidazopirazina como moduladores da atividade
KR20150013189A (ko) 벤조티오펜 화합물 또는 이의 염의 2수화물, 및 이의 제조 방법
TW201121962A (en) Compounds which selectively modulate the CB2 receptor
PT93823B (pt) Processo para a preparacao de derivados de pirimidina e de composicoes farmaceuticas que os contem
CA2931026A1 (fr) Derives d'imidazopyridazine a titre de modulateurs de l'activite du tnf
BR112020018983A2 (pt) Inibidores de canal receptor de potencial transitório de oxadiazol
CA3085353A1 (fr) Quinazolinones en tant qu'inhibiteurs de parp14
BR112019023918A2 (pt) Inibidores de quinase e usos dos mesmos
TW202132307A (zh) 雜環ｒｉｐ１抑制性化合物
KR20190005877A (ko) Trpv4 길항제
WO2010059610A1 (fr) Composés 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine s'utilisant comme modulateurs de la faah et utilisations desdits composés
WO2019138227A1 (fr) Composés pharmaceutiques
JP6617106B2 (ja) 癌の治療用のｆａｓｎ阻害剤として有用なイミダゾリン−５−オン誘導体
CN103373997A (zh) 含有锌结合基的吡啶并萘啶类HDAC和mTOR抑制剂
JP2018087173A (ja) 悪性脳腫瘍治療薬
BR112021004999A2 (pt) composto e método de inibição de cdk7 em um sujeito
CA3068209A1 (fr) Compose heterocyclique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09793640

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011537547

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2744343

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009793640

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13130051

Country of ref document: US